# Abbott Laboratories (ABT) stock news and updates

As of November 16, 2026. Source: https://www.clearthesis.ai/updates/ABT

## Our view on the Abbott Laboratories investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/ABT

## Latest updates on Abbott Laboratories

### CEO Robert Ford's change-in-control agreement set to expire

*November 16, 2026 · filing · significance: minor · signal: neutral*

Abbott notified its top executives on November 11 that it is extending their change-in-control agreements through the end of 2028. These are contracts that provide payouts or protections to leaders if the company is bought or its ownership changes. While most named executive officers received the extension, the company noted that Chairman and CEO Robert B. Ford's agreement will expire on December 31, 2026. This is a technical shift in how the CEO is covered compared to his team, but it does not change his current role leading the company's transition toward medical technology.

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/1800/000110465926127273/0001104659-26-127273-index.htm)

### Abbott heart device shows strong one-year results in stroke prevention

*November 2, 2026 · product · significance: notable · signal: positive*

New data from a year-long study show that Abbott's Amulet 360 device is highly effective at closing the left atrial appendage, a small pouch in the heart where blood clots often form. By sealing this area, the device helps prevent strokes in patients with an irregular heartbeat who cannot take long-term blood thinners. These results are important because they support Abbott's push into more advanced heart care hardware. As the company moves toward becoming a specialized medical technology business, proving the long-term safety and success of its newer devices is key to winning over doctors and taking market share from rivals.

Sources: [PRNewsWire](https://www.prnewswire.com/news-releases/late-breaking-one-year-data-show-abbotts-next-generation-amulet-360-device-continues-to-demonstrate-high-rates-of-left-atrial-appendage-closure-and-low-incidence-of-stroke-302926412.html)

### New system for clearing clogged arteries meets early trial goals

*November 2, 2026 · product · significance: notable · signal: positive*

Abbott reported positive 30-day results for its SonicForce system, which uses acoustic pressure waves to crack calcium buildup in heart arteries. This technique, known as lithotripsy, is similar to how doctors break up kidney stones and allows blood to flow more freely without the need for more invasive surgery. While this was an early-stage trial, the high success rate and lack of complications are promising for Abbott's coronary device business. If this system eventually wins full approval, it would give the company a more modern tool for treating complex heart disease, which is a core part of its long-term growth plan.

Sources: [PRNewsWire](https://www.prnewswire.com/news-releases/abbotts-tectonic-clinical-trial-demonstrates-strong-30-day-outcomes-and-high-procedural-success-for-its-investigational-sonicforce-coronary-intravascular-lithotripsy-system-302925602.html)

### Abbott begins a major trial for its new heart valve replacement device

*October 29, 2026 · news · significance: notable · signal: positive*

Abbott has started a pivotal trial for Cephea, a device designed to replace the heart's mitral valve without the need for open-heart surgery. Mitral valve disease is the most common heart valve problem, and this trial will test how safely and effectively the device works in patients who need a replacement. This is a key step in Abbott's shift toward becoming a focused medical technology company. If successful, Cephea would expand its heart care business by offering a less invasive option for a condition that affects millions of people. While the trial will take time to complete, it shows the company is continuing to build out its pipeline of high-tech hardware.

Sources: [PRNewsWire](https://www.prnewswire.com/news-releases/abbott-initiates-pivotal-trial-for-cephea-device-an-innovative-treatment-for-mitral-heart-valve-disease-302921856.html)

### Argus Research lowered its rating on Abbott to Hold

*October 28, 2026 · analyst · significance: notable · signal: negative*

Argus Research changed its rating from Buy to Hold on Tuesday. This shift comes just a week after the company announced it would spin off its nutrition business, which includes brands like Similac, to focus more on medical devices and heart care. While the average analyst target remains higher at about $121, this move suggests some caution about the transition period ahead. The spin-off is intended to make the company a faster-growing medical technology specialist, but it also removes the steady cash flow that the nutrition segment provided during tougher economic times.

Sources: Argus Research

## Abbott Laboratories earnings

In Q3 2026, reported on October 21, 2026, Abbott Laboratories posted earnings of $1.42 per share against $1.42 expected, and revenue of $13.0 billion against $13.0 billion expected.

The next earnings report is expected on January 28, 2027. Analysts expect $1.64 per share. Revenue is expected around $13.2 billion.

What to watch: Whether organic growth in medical devices can climb back above 10 percent, which is the key to proving the company can grow faster after it spins off its nutrition arm.

## Recent analyst activity on ABT

- October 27, 2026: Argus Research Downgraded to Hold.
- October 23, 2026: Wells Fargo Kept rating at Overweight, raised target from $119. Price target: $120.00.
- October 23, 2026: UBS Set target. Price target: $120.00.
- October 22, 2026: JP Morgan Kept rating at Overweight.
- October 22, 2026: TD Cowen Kept rating at Buy, lowered target from $135. Price target: $118.00.
- October 22, 2026: Wells Fargo Kept rating at Overweight, raised target from $112. Price target: $119.00.

## What's ahead for Abbott Laboratories

- January 28, 2027: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/ABT
